Get the Stockscreener App
1,082.92
1.71%
18.18
Pre-market:
1081.94
-0.98
-0.09%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,082.92, with a volume of 2.55M.
It is up +1.71% in the last 24 hours and up +24.72% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,064.74
Open:
$1072.26
24h Volume:
2.55M
Relative Volume:
0.84
Market Cap:
$965.68B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
38.98
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+6.29%
1M Performance:
+24.72%
6M Performance:
-1.94%
1Y Performance:
+49.32%
1-Day Range:
$1,069.90
$1,093.00
1-Week Range:
$1,022.00
$1,093.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,082.92 | 949.47B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.29 | 554.09B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.40 | 376.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.24 | 295.69B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Vows Global Drug Launches Despite Pricing Pressure From MFN Policy - Bloomberg.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacific Edge Limited (OtherPFGTF), Kura Oncology (KURA) and Eli Lilly & Co (LLY) - The Globe and Mail
Former Nashville councilman denies involvement in alleged $200M Eli Lilly fraud scheme - WZTV
Eli Lilly acquiring Bothell vaccine maker in deal worth up to $1.5 billion - The Business Journals
Eli Lilly’s $4 Billion Vaccine Bet - Forbes
Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion - Yahoo Finance
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? - Yahoo Finance
Eli Lilly lawsuit alleges $200M "fraud scheme" tied to COGIC - localmemphis.com
The $4 Billion Reason Eli Lilly Stock Is Up Today - Yahoo Finance
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? - The Motley Fool
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts - Zacks Investment Research
Kailera’s three-pronged obesity shot shows promise in early trial - BioPharma Dive
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating - 富途牛牛
Eli Lilly Vaccine Push Fuels NYSE Composite Focus - Kalkine Media
Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to know - CNBC
Analyst recommendations: Nvidia, Blackrock, Eli Lilly, Goldman Sachs, Lululemon… - marketscreener.com
Lilly To Buy Vaccine Company For Up To $1.55 Billion - Pulse 2.0
Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine - GeekWire
Lilly Goes on $20 Billion Buying Spree as It Seeks Next Act - Yahoo Finance
Eli Lilly to acquire Bothell’s Curevo Vaccine for $1.5 billion - The Seattle Times
Barclays Raises Target on Eli Lilly (LLY) After Strong Tirzepatide Growth - Insider Monkey
Trump declares perfect health after Walter Reed physical; Eli Lilly spends $4B on three vaccine developers; obesity leveling off in wealthy nations, still rising elsewhere – Morning Medical Update - Medical Economics
Eli Lilly acquires Novo Holdings-backed Limmatech for USD 780m - medwatch.com
Micron Hits $1 Trillion, Overtakes JPMorgan, Walmart And Eli LillyMicron Technology (NASDAQ:MU) - Benzinga
Key facts: Lilly buys 3 vax for up to $4B; PCSK9↓88% LDL‑C↓62%; BofA up GLP‑1 - TradingView
Lilly Follows Upbeat Trials for Cholesterol Shot with $4B M&A Spree - The Daily Upside
GC Biopharma Sells U.S. Affiliate Curevo to Eli Lilly for 459.9 Billion Won - Businesskorea
Eli Lilly Set to Acquire Curevo, LimmaTech Biologics, and Vaccine Co. for $4 Billion - scanx.trade
Lilly buys three vaccine firms to target dementia and infection preventionCHOSUNBIZ - Chosunbiz
How The Eli Lilly (LLY) Narrative Is Evolving With GLP-1 Hopes And Obesity Market Doubts - Yahoo Finance
Eli Lilly spending $3.8 billion to buy vaccine makers - Axios
Eli Lilly Buys 3 Vaccine Companies for $3.8B - Powder & Bulk Solids
GC Green Cross Sells U.S. Affiliate Curevo to Eli Lilly - 아시아경제
Former Metro councilman and pastor accused in 'fraud scheme' to steal $200 million from drug company - News Channel 5 Nashville
Lilly spending nearly $4B to acquire three vaccine developers - Inside INdiana Business
Lilly Is Looking for Its Next Act Beyond the Weight-Loss Boom - Barron's
Lilly to acquire three vaccine developers for up to $3.83 billion By Investing.com - Investing.com Canada
Eli Lilly and Company to acquire 3 vaccine development companies for nearly $4 billion - WTHR
Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B - Law360
Eli Lilly acquires three vaccine companies for infectious disease portfolio - Managed Healthcare Executive
Lilly goes on $20 billion buying spree as company seeks next act - The Daily Gazette
What's Going On With Eli Lilly Stock Tuesday?Eli Lilly (NYSE:LLY) - Benzinga
Lilly to buy three vaccine developers for up to $3.8 billion - MSN
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion - marketscreener.com
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act - Bloomberg.com
Lilly Gets Back Into the Vaccine Business With New Deals - marketscreener.com
LLY: Eli Lilly Acquires Three Vaccine Developers for $3.8 Billio - GuruFocus
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms - Proactive financial news
Lilly buys three vaccine makers; PCSK9 base editor shows promise - BioWorld News
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve - BioPharma Dive
Lilly dives into vaccine research with 3 biotech buyouts - BioPharma Dive
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):